Sevenum / Venlo, the Netherlands, 11 March 2021. The Supervisory Board of SHOP APOTHEKE EUROPE N.V. will propose Henriette Peucker as a new member of the Supervisory Board at the company’s Annual General Meeting on 21 April 2021. Jan Pyttel, who is currently chairing the Supervisory Board, will make his position available and leave the Supervisory Board of his own volition when his term ends with the Annual General Meeting. Jan Pyttel will continue to be associated with the company as a shareholder.
Speaking for the Supervisory Board and the Management Board, current Supervisory Board Deputy Chairman Björn Söder expresses the company’s gratitude to Jan Pyttel: “We want to thank Jan for his long-standing and excellent work on SHOP APOTHEKE EUROPE’S Supervisory Board. With his experience, he has played a key role in shaping the company’s development since the IPO in 2016. In Henriette Peucker, we found an internationally experienced leader who optimally complements the other Board members and will support SHOP APOTHEKE EUROPE N.V. with words and deeds in the next stage of the company’s development.”
Henriette Peucker has many years of experience in the public affairs arena as well as in-depth capital market know-how. She currently heads the Brussels office of Finsbury Glover Hering as a partner and has helped to build up the company’s Public Affairs Department since joining in 2010. Previously, she had held similar positions at Deutsche Börse AG and in the investment banking sections at Schroders and Citigroup.
It is expected that Björn Söder will be appointed as the new Chairman and Frank Köhler as Deputy Chairman at the new Board’s constituent meeting, which will be held following the Annual General Meeting.
ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is one of Europe’s leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.
Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Warsaw, Milan, Paris and Tongeren, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, more than 6.3 million active customers trust SHOP APOTHEKE EUROPE.
Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.
In preparation for the introduction of electronic prescriptions in Germany in summer 2021, the company will further improve the customer experience with focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE’s strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.
SHOP APOTHEKE EUROPE N.V. has been listed on the MDAX stock index since 21 September 2020.
Trade and popular media:
Tel: +49 221 99 53 44 31
Tel: +49 211 75 80 779
Tel.: +31 77 850 6109
Mobile: +49 151 465 31317
This publication constitutes an advertisement. This announcement does not constitute an offer for sale or a solicitation of an offer to purchase securities of SHOP APOTHEKE EUROPE N.V. in any jurisdiction. It does not constitute a securities prospectus. A public offer of securities of SHOP APOTHEKE EUROPE N.V. is not taking place.
Statements contained herein could constitute so-called “forward-looking statements”. Forward-looking statements can be recognized by words such as “might,” “will,” “should,” “plans,” “anticipates,” “anticipates,” “estimates,” “believes,” “intends,” “aims,” “aim” or their negative form or corresponding modifications and comparable terms.
Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, levels of utilization, developments and achievements of the group or industry in which it operates to be materially different than those contained herein or implied. There should be no undue reliance on forward-looking statements. The group will not update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.